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bjectives Our goal was to explore whether antioxidant vitamin C infusion is able to affect the mi-
rocirculation perfusion in patients undergoing elective percutaneous coronary intervention for sta-
le angina.
ackground Periprocedural myocardial injury in the setting of elective percutaneous coronary inter-
ention is associated with increased risk of death, recurrent infarction, and revascularization at follow-
p. Despite excellent epicardial blood ﬂow, impaired microcirculatory reperfusion may persist and in-
reases the risk of vascular recurrences. Post-percutaneous coronary intervention induced-oxidative stress
s one of the potential mechanisms accounting for impaired perfusion.
ethods Fifty-six patients were enrolled in a prospective, single-center, randomized study compar-
ng 1 g vitamin C infusion (16.6 mg/min, over 1 h before percutaneous coronary intervention) versus
lacebo.
esults At the baseline, Thrombolysis In Myocardial Infarction (TIMI) myocardial perfusion grade 2
as observed in 89% and in 86% of patients randomized to the placebo or vitamin C infusion
roup, respectively (p  0.05). After percutaneous coronary intervention, these percentages de-
reased in the placebo group (32%) and in greater measure in the vitamin C group (4%, p  0.01).
omplete microcirculatory reperfusion (TIMI myocardial perfusion grade  3) was achieved in 79%
f the vitamin C-treated group compared with 39% of the placebo group (p  0.01); 8-hydroxy-2-
eoxyguanosine (p  0.002) and 8-iso-prostaglandin F2alpha (p  0.02) plasma levels signiﬁcantly
ncreased in the placebo group while they were signiﬁcantly reduced in the vitamin C-treated group
p  0.0001). TIMI myocardial perfusion grade changes from the baseline showed signiﬁcant correla-
ion with 8-hydroxy-2-deoxyguanosine (p  0.006) or 8-iso-prostaglandin F2alpha (p  0.01) plasma
evels changes.
onclusions In patients undergoing elective percutaneous coronary intervention, impaired microcir-
ulatory reperfusion is improved by vitamin C infusion suggesting that oxidative stress is implicated
n such a phenomenon. (J Am Coll Cardiol Intv 2010;3:221–9) © 2010 by the American College of
ardiology Foundation
rom the *Department of the Heart and Great Vessels “Attilio Reale,” and the †Department of Experimental Medicine, University
f Rome “La Sapienza,” Rome, Italy. The first two authors contributed equally to this work.anuscript received October 5, 2009; accepted October 23, 2009.
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222eriprocedural myocardial injury in the setting of elective
ercutaneous coronary intervention (PCI) for stable angina
s associated with increased risk of death, recurrent infarc-
ion, and revascularization at follow-up (1–3). Periproce-
ural myocardial injury may occur in up to 40% of otherwise
uccessful and angiographically uncomplicated elective proce-
ures (1–3). In these cases, myocardial injury takes place as a
esult of the impairment of downstream coronary microcircu-
ation and is visualized with angiography as a persistence of
bnormally slow myocardial blood flow or no-reflow in the
icrovasculature of the treated coronary artery (4,5).
To this end, the goal of reper-
fusion therapies has shifted to
include reperfusion downstream
at the level of the capillary bed.
Thus, in a substudy of the
Thrombolysis In Myocardial In-
farction (TIMI) 10B trial, excel-
lent epicardial blood flow assessed
by use of corrected Thrombolysis
In Myocardial Infarction frame
count (cTFC) (6) and improved
microvascular perfusion by use of
the Thrombolysis In Myocardial
Infarction myocardial perfusion
grade (TMPG) (7) have been re-
lated to reduced in-hospital 30-
day mortality. These indexes
were also related to 2-year sur-
vival after administration of
thrombolytics (8).
Multiple mechanisms have
been suggested to contribute this
impaired coronary flow, includ-
ing local activation of the coag-
ulation system and intracoronary
thrombus formation, distal em-
bolization of plaque and/or
thrombus from the lesion site,
vasoconstriction of the treated
vessel and the distal microvascu-
lature, and endothelial dysfunc-
tion (4,9).
Post-PCI induced-oxidative stress is another potential mecha-
ism accounting for impaired perfusion. In previous studies, we
nd others have reported an increase in the concentration of
2-isoprostanes (F2-IPs), a stable end product of lipid peroxida-
ion, in coronary sinus blood samples after PCI but not after
iagnostic angiography (10,11).
These findings suggest that coronary angioplasty is asso-
iated with ischemia-related increase in oxidative stress.
itamin C is an antioxidant molecule that quenches reactive
xygen species (ROS), inhibiting ROS-mediated nitric
bbreviations
nd Acronyms
TFC  corrected
hrombolysis In Myocardial
nfarction frame count
TpI  cardiac troponin I
2-IPs  F2-isoprostanes
R  heart rate
s-CRP  high-sensitivity
-reactive protein
QR  interquartile range
AD  left anterior
escending coronary artery
VEF  left ventricular
jection fraction
AP  mean arterial blood
ressure
O  nitric oxide
CI  percutaneous
oronary intervention
OS  reactive oxygen
pecies
Cr  serum creatinine
evels
MPG  Thrombolysis In
yocardial Infarction
yocardial perfusion grade
-iso-PGF2alpha  8-iso-
rostaglandin F2alpha
-OHdG 
-hydroxy-2-deoxyguanosinexide (NO) inactivation (12–14).This effect is likely to account for arterial dilation occurring
n coronary and extracoronary districts after intravenous infu-
ion of ascorbic acid (15–18). However, it has never been
nvestigated whether vitamin C may influence the impairment
f microcirculation perfusion occurring after PCI. We, there-
ore, performed an interventional study in patients undergoing
lective PCI for stable angina to explore whether vitamin C
nfusion is able to affect the microcirculation perfusion in this
ubset of patients. Furthermore, we measured markers of
xidative stress to corroborate the antioxidant property of
itamin C in this experimental model.
ethods
tudy participants. This was a prospective, single-center,
lacebo-controlled, randomized study. We studied 56 pa-
ients (47 men and 9 women, mean age 67 [50 to 84] years)
ith clinically stable class I or II effort angina pectoris
ccording to the Canadian Cardiovascular Society criteria
19) and a single de novo lesion in a native coronary artery
hat was scheduled for elective PCI (Table 1). Angiographic
nclusion criteria for interventional study was a target vessel
eference diameter of 2.5 to 3.5 mm, all type A or type B
esions, as described by the American College of Cardiology/
Table 1. Clinical and Angiographic Characteristics of the Patients
Placebo
(n  28) p Value
Vitamin C
(n  28)
Age (yrs) 68 9 0.05 66 8
Men 23 (82) 0.05 24 (86)
CVD familiarity 17 (61) 0.05 14 (50)
Hypertension 20 (71) 0.05 20 (71)
Dyslipidemia 20 (71) 0.05 19 (68)
Current smoker 13 (46) 0.05 11 (39)
Diabetes mellitus 15 (54) 0.05 18 (64)
Pharmacological therapy
Oral hypoglycemic 12 (43) 0.05 11 (39)
Insulin treatment 2 (7) 0.05 3 (10)
Statins 19 (68) 0.05 16 (57)
Nitrates 13 (46) 0.05 16 (57)
ACE inhibitors 15 (54) 0.05 12 (43)
Beta-blockers 9 (32) 0.05 10 (36)
Calcium antagonists 7 (25) 0.05 6 (21)
Target vessel
Left anterior descending artery 18 (64) 0.05 15 (54)
Left circumﬂex artery 3 (11) 0.05 6 (21)
Right coronary artery 7 (25) 0.05 7 (25)
Procedural data
Diameter stenosis (%) 80.1 9.7 0.05 83.5 11.5
Stent diameter (mm) 3.0 0.39 0.05 3.1 0.37
Stent length (mm) 19.8 7.1 0.05 20.8 7.5
Balloon pressure (atm) 16.5 1.4 0.05 16.9 1.1
Values are mean SD or n (%).ACE angiotensin-converting enzyme; CVD cardiovascular disease.
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223merican Heart Association Task Force (20), a lesion
ength 33 mm, which would be covered with a single
tent, diameter stenoses 70% and 100%, and a TIMI
ow grade 1.
Patients were selected among the 92 consecutive patients
eferred over an 8-month period (September 2007 and
ecember 2008) to the Department of the Heart and Great
essels “Attilio Reale,” University of Rome “La Sapienza,”
taly. Clinical exclusion criteria were contraindication to
spirin or clopidogrel (n  2), previous myocardial infarc-
ion (13 patients), multivessel interventions (n  12), graft
essel disease (n  5), platelet count 100,000/mm3 (n 
), and history of bleeding diathesis (n  2). Informed
onsent was obtained from each participating subject, and
he protocol was approved by the University of Rome “La
apienza” Ethics Committee.
tudy design. With the aim to evaluate the effect of vitamin
infusion on indexes of reperfusion (i.e., cTFC, TMPG)
nd inflammatory and oxidative stress markers after PCI, we
lanned an interventional study. All eligible patients were
andomly assigned in a 1:1 manner to receive ascorbic acid
olution (1 g of vitamin C Vita, [Sanofi-Aventis, Milan
taly] diluted in 250 ml of isotonic saline infused at 16.6
g/min, 4.2 ml/min, over 1 h before PCI) or placebo
isotonic saline infused at 4.2 ml/min over 1 h before PCI).
All the participants were studied after a 12-h fast.
lood samples were collected at baseline (before the start
f procedure) and after 60 min from the end of PCI to
easure 8-iso-prostaglandin F2alpha (8-iso-PGF2alpha)
nd 8-hydroxy-2-deoxyguanosine (8-OHdG), 2 blood mark-
rs of oxidative stress, and high-sensitivity C-reactive protein
hs-CRP) serum levels.
Serum cardiac-Troponin I (cTpI) was measured at base-
ine before the procedure, every 6 h over the next 2 days, and
hereafter if these were abnormal values. cTpI levels were
easured using an automated enzyme immuno assay system
Dimension RXL MAX, Siemens Healthcare Diagnostic,
schborn, Germany) with the upper limit of normal being
.05 ng/ml in our laboratory. Serum creatinine levels (SCr)
ere measured in the morning of the day before coronary
ngiography and of the day after PCI.
Left ventricular ejection fraction (LVEF) was calculated
y the biplane Simpson’s rule, as recommended by the
merican Society of Echocardiography at baseline and 72 h
fter PCI.
rimary and secondary end points. The primary end point
as the assessment of cTFC and TMPG changes occurring
fter elective PCI. Secondary end points included: 1) the
valuation of the effect of vitamin C infusion on inflamma-
ory and oxidative stress markers after PCI; 2) mean peak
alues of cTpI after the procedure; and 3) major adverse
linical events defined as a composite of death, acute
yocardial infarction, and target vessel revascularization upo 6 months after interventions as assessed by telephone bontact or scheduled office visit by operators who were
linded to treatment allocation at the time of PCI and to
ny clinical, laboratory, and angiographic data.
rocedure of stent implantation. During the 24 h before the
rocedure and thereafter, all patients received aspirin (100
g daily) and clopidogrel (loading dose of 300 mg, followed
y 75 mg daily for at least 6 months). Preparation and
ercutaneous access were performed according to standard
ospital procedures. After percutaneous access was ob-
ained, an intravenous bolus of 5,000 U of unfractionated
eparin was administered, with sufficient supplements (if
ecessary) to maintain an activated clotting time 250 s
uring intervention and for 2 h after stent implantation. A
aseline angiography of the involved vessel was performed
n at least 2 near orthogonal views that showed the target
esion free of foreshortening or vessel overlap, using a 6-F
iagnostic catheter. The angiograms included at least 2 cm
f catheter to allow for accurate quantitative coronary
ngiographic measurements. After identification of the
arget lesion that met all eligibility criteria, those patients
ho continued to meet eligibility criteria were randomized
o placebo or ascorbic acid administration and received a
nique study identification code.
The target lesion was crossed with a 0.014 exchange-
ength guidewire, and a single pre-dilation with an appro-
riately sized balloon was performed by inflating the balloon
o the nominal pressure over a 15-s period. Within 1 min
rom balloon dilation, a sirolimus-eluting stent (Cypher,
ordis, Johnson & Johnson, Amersfoort, the Netherlands)
as implanted. Stent deployment was achieved with high
ressure balloon inflation (more than 15 atm) without any
ost-dilation. No direct stenting was performed. The proce-
ure was considered successful when stent placement was
ssociated with a residual stenosis 30% and a TIMI flow
rade 3.
ngiographic assessment. Angiograms recorded before and
mmediately after the procedure were assessed with the aid
f the automated edge detection system (Centricity Cardi-
logy CA 1000, GE Medical Systems, Milwaukee, Wis-
onsin). The quantitative measurements were performed on
nd-diastolic frames by 1 operator. The same projections
ere used at all time points. The central filled nontapered
atheter tip was used for calibration. Early lumen gain was
alculated as the difference between minimal lumen diam-
ter at the end of the intervention and before balloon
re-dilation.
During angiography, imaging was recorded from the time
f first injection of the coronary arteries until venous filling
as observed and continued for at least 3 cardiac cycles at
he washout phase. Epicardial coronary arteries were visu-
lized in multiple views, including cranial and caudal angu-
ations. Selective angiography was performed with an auto-
atic injector (ACIST HD101, Eden Prairie, Minnesota),
y using a total volume of 10 ml iopromide (Ultravist 370,
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224chering AG, Berlin, Germany), at a rate of 2.0 ml/s for left
oronary arteries, and a total volume of 8 ml iopromide at a
ate of 1.0 ml/s for right coronary arteries, at 450 PSI.
aseline and post-interventional TIMI flow grade, cTFC,
nd TMPG were evaluated by an independent core labora-
ory (ROMA [Ricerche Orientate alla Malattia Ateroscle-
otica], Rome, Italy). The operators who performed the
valuation were unaware of the study protocol and of the
atient’s characteristics. Digital angiograms were analyzed
ff-line with the use of an automated edge detection system
Cardiovascular Medical System, MEDIS Imaging Sys-
ems, Leiden, the Netherlands).
IMI ﬂow grade. Angiographic TIMI flow grade of the
iseased artery was estimated before and after completion of
CI according to 4 grades of flow, as previously described (21).
TFC. The analysis of coronary flow was done according to
he TIMI frame count method by Gibson et al. (21). The
umber of frames required for contrast to first reach
tandardized distal coronary landmarks was measured by the
ine viewer frame counter. Cine film speed was 30 frames
er second. Extrasystolic and post-extrasystolic beats were
arefully excluded from analysis. The first frame used for
IMI counting was the first frame where the dye column
xtended more than 70% of the arterial lumen with antero-
rade motion. The last frame counted was the first frame
here the dye entered the distal landmark branch. The
ollowing distal landmarks were used for analysis: distal
ifurcation of the left anterior descending coronary artery
LAD) known as moustache, pitch fork, or whale’s tail;
istal branch of the lateral left ventricular wall artery
urthest from the coronary ostium for the left circumflex
rtery; first branch of posterolateral artery for the right
oronary artery. The corrected TIMI frame count was
alculated by dividing the LAD TIMI frame count by 1.7,
nd the mean value of both investigators’ measurements was
onsidered as the reference value for statistical analysis.
ormal values were defined as follows: 36.2  2.6 frames
or the LAD; 22.2  4.1 for the left circumflex artery; 20.4
.0 frames for the right coronary artery. Values above the
ormal frame count were considered suggestive for impair-
ent of microcirculation.
MPG. The TMPG (6) was used to assess the filling and
learance of contrast in the myocardium. TMPG0 was
efined as no apparent tissue-level perfusion (no ground-
lass appearance of blush or opacification of the myocar-
ium) in the distribution of the culprit artery. TMPG1
ndicated a presence of myocardial blush but no clearance
rom the microvasculature (blush or a stain present on the
ext injection). TMPG2 indicated that the blush cleared
lowly (blush strongly persistent and diminished minimally
r not at all during 3 cardiac cycles of the washout phase).
MPG-3 indicated that blush began to clear during wash-
ut (blush minimally persistent after 3 cardiac cycles of
ashout). snalytical measurements. Blood samples were drawn from
n antecubital vein with a 21-gauge needle and then mixed
n a tube with 0.13 mmol/l sodium citrate (ratio 9:1).
amples were collected before and 60 min after the
rocedure.
Blood samples were immediately centrifuged at 2,000
pm for 20 min at 4°C, and the supernatant was collected
nd stored at 80°C until measurement. Plasma levels of
-OHdG (Quantikine R&D Systems, Minneapolis, Min-
esota) and hsCRP (Tema Ricerca Srl, Bologna, Italy) were
easured with a commercial immunoassay. Intra-assay and
nterassay coefficients of variation were 2.1% and 4.5% for
-OHdG, and 8.3% and 7.8% for hsCRP. The analytical
easurements were performed blinded to any clinical and
ngiographic data.
-iso-PGF2alpha. NaOH (10 N) was added to the samples
nd heat at 45°C for 2 h, then were added with 100 l of
oncentrated HCl (12 N) per 500 l of hydrolyzed sample.
he samples were centrifuged for 5 min at 14,000 rpm in a
icrocentrifuge. The levels of 8-iso-PGF2alpha in clear
upernatant were measured with a commercial immunoas-
ay (Assay the Designs, Ann Arbor, Michigan). Intra-assay
nd interassay coefficients of variation were 5.7% and 5.8%.
tatistical analysis. Differences between percentages were as-
essed by chi-square test or Fisher exact test. Student unpaired
test and Pearson product-moment correlation analysis were
sed for normally distributed continuous variables. Appropri-
te nonparametric tests (Mann-Whitney U test and Spearman
ank correlation test) were employed for all the other variables.
ultiple linear regression analyses were performed to further
uantify the relationship between clinical and biochemical
ariables. The differences between baseline and post-treatment
alues were analyzed with the Wilcoxon signed rank test.
A sample size of 20 patients undergoing vitamin C
nfusion provided the intervention study with 80% power to
etect a 50% improvement in TMPG with respect to the
lacebo group. This minimum sample size could be in-
reased to 28 patients in order to keep the degrees of
reedom for the assessment of treatment effect in the
tatistical analysis at the required level. Sample size calcu-
ation was performed using the software nQuery Advisor,
ersion 5.0 (Statistical Solutions, Saugus, Massachusetts).
ata are presented as mean (1 SD) or as median and
nterquartile range (IQR) (25th, 75th percentile). Only p
alues 0.05 were regarded as statistically significant. All
ests were 2-tailed, and analyses were performed using a
omputer software package (Statistica version 7, Stat- Soft
nc., Tulsa, Oklahoma, or Statistical Package for the Social
ciences, version 16.0, SPSS Inc., Chicago, Illinois).
esults
he enrolled patients completed all phases of the study. No
ide effects were observed during or after ascorbic acid or
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225lacebo infusion. Table 1 shows baseline demographic and
linical characteristics of patients according to randomiza-
ion at the infusion treatment. Age, sex, risk factor distri-
ution, and concomitant pharmacological treatment did not
iffer between the groups (Table 1).
Forty-five patients (22 in the vitamin C and 23 in the
lacebo group) experienced angina during stent deploy-
ent; of those, 12 patients (6 for each group) showed
ignificant ST-segment downsloping during balloon infla-
ion. The time duration of balloon occlusion did not differ
etween treated patients and control subjects (22  9 s vs.
3 9 s, respectively, p NS). cTpI was always within the
pper limits of normal values in both groups. The median
bsolute increase in serum troponin level was similar be-
ween control patients and the ascorbic acid group (median
IQR] 0.027 [0.05 to 0.032] vs. 0.008 [0.02 to 0.013]
g/ml, respectively, p  0.0832).
The SCr levels increased from (median [IQR]) 0.97 (0.78
o 1.15) mg/dl to 1.26 (1.02 to 1.33) mg/dl (p  0.0001) in
he placebo group within 24 h of contrast administration
ut decreased from 0.90 (0.89 to 1.08) to 0.86 (0.75 to 0.93)
p  0.001) in patients receiving ascorbic acid. After 24 h of
he procedure end, the 2 groups significantly differed in SCr
hanges from the baseline (p  0.001).
Baseline mean values of LVEF were similar in both the
itamin C and control groups (52.3  4.3% vs. 53.7% 
.9%, pNS). After intervention, LVEF improved in both
roups with a higher increase in vitamin C-treated patients
ompared with the placebo group (58.3  2.9% vs. 54.1 
.7%, respectively, p  0.03). Vitamin C-treated patients
howed a greater improvement of LVEF after the procedure
ompared with that observed in the control group (p  0.01).
Baseline mean values of heart rate (HR) and mean arterial
lood pressure (MAP) were overlapping between the 2
reatment groups (vitamin C vs. control group; HR 72.4 
.9 vs. 69.5  10.6, p  NS; MAP 104  17.1 vs. 105.2 
7.2, p  NS). Patients receiving ascorbic acid infusion
howed similar changes in HR (72.9  12 vs. 71.7  11.9,
 NS) and MAP (102  20.7 vs. 103.9  19.4, p  NS)
ompared with those receiving placebo infusion.
ngiographic and interventional data. The implantation of
single stent was successful in all patients with complete
overing of the vessel lesion length and without quantitative
oronary angiographic residual stenosis within the stent.
urthermore, angiographic images obtained after stent de-
loyment did not show signs of endothelial dissection in the
reas proximal or distal to the stent struts. There were no
ifferences in early lumen gain and final diameter stenosis
etween the 2 groups (Table 1).
eperfusion indexes. The cTFCs before stent implantation
ere similar between the 2 groups (placebo vs. vitamin C
nfusion: 40.2  9.9 frames/s vs. 36.1  8.9 frames/s, p 
.05). Seventy-one percent of patients allocated to the placebo
roup and 86% of those assigned to the vitamin C group hadTFC ranging from 20 to 40 frames/s (p  0.05); the
emaining patients (n  8 in the placebo group and n  4 in
he vitamin C group) had cTFC more than 40 frames/s (p 
.05). After PCI, both groups (placebo 30.3 8.0 frames, p
.0001; vitamin C infusion group 21.3  5.2 frames, p 
.0001) showed a statistically significant reduction in cTFC
ompared with baseline values; nevertheless, at the end of
nfusion, cTFC was significantly lower in the vitamin C group
median change 41%) compared with the placebo group
median changes23%, p 0.0001) (Fig. 1A). Interestingly,
patient (4%) in the placebo group and 16 (57%) patients in
Figure 1. cTFC and TMPG Before and After Placebo or Vitamin C Infusion
Corrected Thrombolysis In Myocardial Infarction frame count (cTFC) (A) and
Thrombolysis In Myocardial Infarction myocardial perfusion grade (TMPG)
(B) before and after placebo or vitamin C infusion. *McNemar chi-square;
**Fisher exact test. Triangles in B contain numbers of each TMPG grade (0,
1, 2, 3) before and after percutaneous coronary intervention (PCI) in each
group. TIMI  Thrombolysis In Myocardial Infarction.
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226itamin C group reached lower-risk (20 frames/s) cTFC
lass (p  0.0001).
At the baseline, TMPG 2 was observed in 89% and in
6% patients randomized to the placebo or vitamin C infusion
roup, respectively (p  0.05). After PCI, these percentages
ecreased in the placebo group (32%) and in greater measure in
he vitamin C group (4%) (p  0.01) (Fig. 1B).
A normal perfusion (TMPG  3) was detected in 79%
n  22) of patients allocated to ascorbic acid compared with
9% (n  11) of those allocated to placebo (p  0.01). In the
verall population, TMPG and cTFC changes from the
aseline showed a significant correlation (Rs 0.60, p 0.05).
ndexes of oxidative stress and inﬂammation. At the base-
ine, the 2 intervention groups did not differ in serum values
f 8-OHdG (vitamin C group 3.7  1.4 ng/ml vs. placebo
roup 3.4  1.1 ng/ml, p  0.3733), of 8-iso-PGF2alpha
median [IQR] 142.5 [85.5 to 187.5] pg/ml vs. 126.0 [85.0
o 170.0] pg/ml, p  0.4172), and hs-CRP (1.3  0.9 mg/l
s. 1.5  0.8 mg/l, p  0.5397). Thus, before the start of
he interventional procedure, 8-OHdG and 8-iso-
GF2alpha plasma levels were significantly correlated in the
8 studied patients (Rs  0.56, p  0.0001). The hs-CRP
Figure 2. 8-OHdG and 8-iso-PGF2alpha Before and After Placebo or Vitamin
8-hydroxy-2-deoxyguanosine (8-OHdG) (A) and 8-iso-prostaglandin F2alpha (8-is
(lower panel). The differences between baseline and post-treatment values were anid not show a significant correlation with either index of
xidative stress (data not shown).
Sixty minutes after balloon inflation 8-OHdG (4.2  1.1
g/ml, p  0.002) and 8-iso-PGF2alpha (161.5 [117.5 to
90.0] pg/ml, p 0.02) plasma levels significantly increased
n the placebo group; on the contrary, the 2 indexes of
xidative stress significantly decreased in the vitamin
-treated group (8-OHdG 2.6  1.1 ng/ml, p  0.0001;
-iso-PGF2alpha 50 [20.7 to 102.5] pg/ml, p  0.0001).
ccordingly, as shown in Figures 2A and 2B, 60 min after
alloon inflation the 2 groups significantly differed in serum
alues of 8-OHdG (p 0.001) and of 8-iso-PGF2alpha (p
.0001). After 60 min of the interventional procedure,
-OHdG and 8-iso-PGF2alpha plasma levels were still
ignificantly correlated in the overall population (Rs  0.49,
 0.0002).
ivariate correlations. In all studied patients, cTFC changes
rom the baseline did not show a significant correlation with
-OHdG (Rs0.22, p 0.0972) or 8-iso-PGF2alpha (Rs
0.25, p  0.0604) plasma level changes from baseline.
n contrast, TMPG changes from the baseline showed a
ignificant correlation with 8-OHdG (Rs  0.36, p 
sion
2alpha) (B) in the placebo group (upper panel) and in the vitamin C groupC Infu
o-PGF
alyzed with the Wilcoxon signed rank test.
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227.006) or 8-iso-PGF2alpha (Rs  0.35, p  0.01) plasma
evel changes from baseline.
dverse cardiac events. There were no adverse events during
ospitalization in both groups. None of the patients died
uring the follow-up. No thrombosis-related events occurred
fter a mean time of 15 4.5 months after interventions. The
umulative event rate was 7.2%: 3 patients (5.3%) in the
lacebo group and 1 patient (3.5%) in the vitamin C group
eeded restenosis-related target vessel revascularization.
iscussion
he present study provides evidence that vitamin C infusion
mproves myocardium reperfusion via inhibition of oxida-
ive stress in patients undergoing PCI. Impaired microcir-
ulatory perfusion is usually detected in patients undergoing
CI. According to other studies showing reduced TMPG
anging from 52% to 94% (22–26), our patients at baseline
howed TMPG 2 in 87.5% of the recruited patients. This
ould be dependent on the coexistence of risk factors such as
iabetes and hypertension, which could hamper microvas-
ular perfusion (27,28).
PCI restoration of epicardial flow does not necessarily
ead to restoration of tissue level or microvascular perfusion.
hus, previous studies showed that achievement of TMPG
2 can be observed in about 65% to 85% of all patients
ndergoing PCI for acute coronary syndrome; this percent-
ge fell to 25% to 60% considering only the subgroup of
atients achieving optimal microvascular reperfusion
TMPG  3) (22–26). A similar reperfusion rate was
bserved in our placebo-allocated group (39%) while the
itamin C-allocated group showed a much higher reperfu-
ion rate (79%) suggesting that vitamin C infusion enhances
oronary perfusion at a microcirculatory level.
A potential role of oxidative stress in impairing myocardium
eperfusion has been suggested by the elevation of several
arkers of oxidative stress occurring after PCI likely as a
onsequence of the ischemia-reperfusion phenomenon
11,29–31). More recently, an inverse association between
yeloperoxidase, a reactive oxidant species-generating en-
yme, and TMPG was observed, but a cause-effect relationship
as not determined (32). Our data extend these findings as we
how that oxidative stress is implicated in impairing microcir-
ulatory flow. Thus, infusion of vitamin C, which is known to
uench oxygen radicals, was associated with improvement of
icrocirculatory perfusion coincidentally with inhibition of
xidative stress.
The fact that vitamin C infusion blunted in vivo the
ncrease of 2 markers of oxidative stress, namely 8-OHdG
nd F2-IPs, is consistent with previous studies showing that
uch a pharmacological route exerts an antioxidant effect
13,33–36). This is likely dependent on the fact that vitamin
infusion is associated with supra-physiologic blood con-
entrations (i.e., millimolar), which are necessary to scav- mnge superoxide radicals and to eventually exert an antiox-
dant property (13,33–36). This pharmacological property
as been suggested to account for the vasodilating property
f vitamin C that has been observed in either extracoronary
r coronary macro-circulation (17,37–39). Notably, Kauf-
ann et al. (40) found that intravenous vitamin C is also
ble to improve microcirculatory flow as shown by the fact
hat it increased coronary flow reserve in smokers. This
ffect could be achieved via vitamin C interference with NO
ioactivity/biosynthesis. Thus, vitamin C stabilizes BH4
evels by regenerating BH4 from its oxidized form (34,41–
3). As oxidative inactivation of BH4 impairs endothelial NO
ynthase (44–46), BH4 stabilization by vitamin C could
estore endothelial NO synthase activity and NO biosynthesis
47,48). Also, vitamin C inhibits nicotinamide adenine dinu-
leotide phosphate oxidase (13,49–52), the main cellular
ource of superoxide radicals (53), and scavenges superoxide
adicals, 2 effects that result in reduced NO inactivation by
OS.
Inhibition of F2-IPs could represent, per se, another putative
echanism that, however, has been recently questioned
54,55). Thus, F2-IPs exert a vasoconstriction effect on the
rterial wall (56–58) and could be responsible for post-PCI
o-reflow phenomenon as they sharply increase after PCI
11,12,29). A recent study, however, showed that after PCI the
ocal (coronary) blood concentration was too low to exert a
oronary vasoconstriction effect (59). Based on these data, the
ecrease of F2-IPs by vitamin C should be regarded, at the
oment, as a mere epiphenomenon of the antioxidant property of
itamin C.
This study has implications and limitations. An interest-
ng finding of the study was the higher increase of LVEF in
he vitamin C-treated group compared with the placebo
roup. Even if this effect on ventricular function could have
beneficial impact in the clinical history of vitamin
-treated patients, the very few vascular outcomes do not
ttribute a clinical relevance to this potentially interesting
ata. Further study is, therefore, necessary to see if vitamin
infusion is actually associated with improved clinical
utcome in patients undergoing PCI.
Even if the increase of microvascular reperfusion was
oincident with oxidative stress reduction, a cause-effect
elationship cannot be established as no biological markers
f arterial dilation were investigated.
Vitamin C has a short half-life (60); therefore, reperfusion
melioration would probably be a consequence of a short-term
ffect on arterial dilation; other mechanisms, such as a decrease
f micro-embolization, which would require a prolonged effect,
re unlikely but cannot be excluded.
onclusions
e show that in patients undergoing elective PCI, impaired
icrocirculatory reperfusion is improved by vitamin C
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228nfusion. This suggests that oxidative stress is implicated in
uch a phenomenon and provides a rationale to test the
linical efficacy of vitamin C infusion in this setting.
eprint requests and correspondence: Prof. Francesco Violi,
rima Clinica Medica, Viale del Policlinico 155, Roma 00161,
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